Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project.
Antipsychotics
COVID-19
Dementia
Mortality
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
06 01 2023
06 01 2023
Historique:
received:
21
05
2022
accepted:
25
12
2022
entrez:
7
1
2023
pubmed:
8
1
2023
medline:
11
1
2023
Statut:
epublish
Résumé
Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia and medication use with mortality in the hospitalized and discharged patients who suffered from COVID-19. We conducted an open-cohort observational study based on electronic patient records from nine geriatric care clinics in the larger Stockholm area, Sweden, between February 28, 2020, and November 22, 2021. In total, we identified 5122 hospitalized patients diagnosed with COVID-19, out of which 762 (14.9%) patients had concurrent dementia and 4360 (85.1%) were dementia-free. Patients' age, sex, baseline oxygen saturation, comorbidities, and medication prescription (cardiovascular and psychotropic medication) were registered at admission. The hazard ratios (HRs) with 95% confidence intervals (CIs) of in-hospital, 30-day, 90-day, 365-day post-discharge, and overall mortality during the follow-up were obtained. Then, the associations of dementia and medication use with mortality were determined using proportional hazards regression with time since entry as a time scale. After adjustment, dementia was independently associated with 68% higher in-hospital mortality among COVID-19 patients compared to patients who were dementia-free at admission [HRs (95% CI) 1.68 (1.37-2.06)]. The increase was consistent post-discharge, and the overall mortality of dementia patients was increased by 59% [1.59 (1.40-1.81)]. In addition, the prescription of antipsychotic medication at hospital admission was associated with a 70% higher total mortality risk [1.70 (1.47-1.97)]. The clinical co-occurence of dementia and COVID-19 increases the short- and long-term risk of death, and the antipsychotics seem to further the risk increase. Our results may help identify high-risk patients in need of more specialized care when infected with COVID-19.
Sections du résumé
BACKGROUND
Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia and medication use with mortality in the hospitalized and discharged patients who suffered from COVID-19.
METHODS
We conducted an open-cohort observational study based on electronic patient records from nine geriatric care clinics in the larger Stockholm area, Sweden, between February 28, 2020, and November 22, 2021. In total, we identified 5122 hospitalized patients diagnosed with COVID-19, out of which 762 (14.9%) patients had concurrent dementia and 4360 (85.1%) were dementia-free. Patients' age, sex, baseline oxygen saturation, comorbidities, and medication prescription (cardiovascular and psychotropic medication) were registered at admission. The hazard ratios (HRs) with 95% confidence intervals (CIs) of in-hospital, 30-day, 90-day, 365-day post-discharge, and overall mortality during the follow-up were obtained. Then, the associations of dementia and medication use with mortality were determined using proportional hazards regression with time since entry as a time scale.
RESULTS
After adjustment, dementia was independently associated with 68% higher in-hospital mortality among COVID-19 patients compared to patients who were dementia-free at admission [HRs (95% CI) 1.68 (1.37-2.06)]. The increase was consistent post-discharge, and the overall mortality of dementia patients was increased by 59% [1.59 (1.40-1.81)]. In addition, the prescription of antipsychotic medication at hospital admission was associated with a 70% higher total mortality risk [1.70 (1.47-1.97)].
CONCLUSIONS
The clinical co-occurence of dementia and COVID-19 increases the short- and long-term risk of death, and the antipsychotics seem to further the risk increase. Our results may help identify high-risk patients in need of more specialized care when infected with COVID-19.
Identifiants
pubmed: 36609457
doi: 10.1186/s13195-022-01154-w
pii: 10.1186/s13195-022-01154-w
pmc: PMC9817345
doi:
Substances chimiques
Psychotropic Drugs
0
Antipsychotic Agents
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Informations de copyright
© 2023. The Author(s).
Références
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Lancet Psychiatry. 2021 Sep;8(9):797-812
pubmed: 34274033
Acta Paediatr. 2020 Dec;109(12):2459-2471
pubmed: 32951258
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Am Geriatr Soc. 2020 May;68(5):912-917
pubmed: 32212386
Alzheimers Dement. 2020 Nov;16(11):1571-1581
pubmed: 32789951
Clin Neurol Neurosurg. 2021 Jan;200:106349
pubmed: 33172719
PLoS One. 2019 Mar 14;14(3):e0213825
pubmed: 30870526
BMC Geriatr. 2014 Jan 28;14:10
pubmed: 24472217
Front Neurol. 2012 May 07;3:73
pubmed: 22586419
Alzheimers Dement. 2021 Aug;17(8):1297-1306
pubmed: 33559975
Health Policy Technol. 2020 Dec;9(4):598-612
pubmed: 32904437
Cochrane Database Syst Rev. 2022 Dec 7;12:CD015477
pubmed: 36473651
Psychogeriatrics. 2022 May;22(3):402-412
pubmed: 35128762
Schizophr Res. 2021 Mar;229:53-54
pubmed: 33631466
J Am Geriatr Soc. 2020 Aug;68(8):1673-1676
pubmed: 32516441
Alzheimers Res Ther. 2021 Jun 12;13(1):111
pubmed: 34118974
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Gerontol Geriatr Med. 2021 Dec 01;7:23337214211057392
pubmed: 34888405
Brain. 2020 Oct 1;143(10):3104-3120
pubmed: 32637987
Front Aging Neurosci. 2020 Oct 26;12:588872
pubmed: 33192483
Geriatr Gerontol Int. 2021 Feb;21(2):172-177
pubmed: 33340212
J Am Med Dir Assoc. 2019 Mar;20(3):323-329.e2
pubmed: 30824220
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
BMC Med. 2014 Oct 31;12:192
pubmed: 25358236
Pharmacol Res. 2021 May;167:105534
pubmed: 33677103
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Lancet Respir Med. 2022 Sep;10(9):863-876
pubmed: 35568052
Alzheimers Dement. 2021 Nov;17(11):1818-1831
pubmed: 33881211
J Alzheimers Dis. 2021;82(3):883-898
pubmed: 34092646
JAMA Psychiatry. 2021 Nov 1;78(11):1208-1217
pubmed: 34313711
J Am Med Dir Assoc. 2020 Nov;21(11):1555-1559.e2
pubmed: 32978065
J Alzheimers Dis. 2020;78(4):1775-1782
pubmed: 33285638
J Alzheimers Dis. 2022;89(2):681-693
pubmed: 35912744
BMJ Open. 2022 Jan 24;12(1):e050628
pubmed: 35074810
Nat Commun. 2022 Jun 2;13(1):3082
pubmed: 35654888
Drugs Aging. 2022 Jun;39(6):467-475
pubmed: 35726042
PLoS One. 2021 Oct 21;16(10):e0258916
pubmed: 34673821
J Alzheimers Dis Rep. 2018 Feb 2;2(1):1-26
pubmed: 30480245
Arch Gerontol Geriatr. 2021 Jul-Aug;95:104388
pubmed: 33713880
PLoS One. 2015 Feb 19;10(2):e0116538
pubmed: 25695768
J Clin Med. 2022 Sep 03;11(17):
pubmed: 36079143
BMC Med. 2020 Jul 15;18(1):215
pubmed: 32664944
Alzheimers Dement. 2021 Jun;17(6):1056-1065
pubmed: 33399270
Front Psychiatry. 2020 Oct 22;11:585540
pubmed: 33192732
Mayo Clin Proc. 2020 Oct;95(10):2189-2203
pubmed: 33012349
JAMA Netw Open. 2022 May 2;5(5):e2210743
pubmed: 35522282
Arch Gerontol Geriatr. 2021 Mar-Apr;93:104299
pubmed: 33285424
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
Geriatr Nurs. 2021 Sep-Oct;42(5):1230-1239
pubmed: 33824009
Br J Psychiatry. 2021 Jul;219(1):368-374
pubmed: 32713374